Cabaletta Bio reports 2025 financial results

Cabaletta Bio has released its fourth quarter and full-year 2025 financial results, along with a business update. The company's Rese-cel myositis program is on track for a Biologics License Application (BLA) submission in 2027. This timeline is based on a registrational cohort design involving 17 patients, which includes an outpatient dosing option. These updates indicate steady progress in Cabaletta Bio's clinical development pipeline and regulatory strategy.